Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Analysis-Directed Therapy in Advanced NSCLC
NCT00705549Phase 2Terminated
- Sponsor
- Hellenic Oncology Research Group
- Start
- Feb 2008
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine, cisplatin, docetaxel, vinorelbine and pemetrexed in non-small cell lung cancer (NSCLC) (11 arms), sponsored by Hellenic Oncology Research Group. Primary endpoint: Objective Response Rate. Started Feb 2008; status: terminated.
02
Drugs
gemcitabinecisplatindocetaxelvinorelbinepemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00705549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00705549.